Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report

Maternal vaccination for Influenza and Tetanus, Diphtheria, acellular Pertussis (TDaP) have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against severe acute...

Full description

Saved in:
Bibliographic Details
Published inBMC pediatrics Vol. 21; no. 1; p. 138
Main Authors Paul, Gilbert, Chad, Rudnick
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.03.2021
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Maternal vaccination for Influenza and Tetanus, Diphtheria, acellular Pertussis (TDaP) have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). There is a significant and urgent need for research regarding safety and efficacy of vaccination against SARS-CoV-2 during pregnancy. A vigorous, healthy, full-term female was born to a COVID-19 naïve mother who had received a single dose of messenger RNA (mRNA) vaccine for SARS-CoV-2 3 weeks prior to delivery. IgG cord blood antibodies were detected to SARS-CoV-2 at the time of birth. Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1471-2431
1471-2431
DOI:10.1186/s12887-021-02618-y